CTRI/2019/06/019832已完成未知
A Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference Medicinal Product of Paliperidone Palmitate Prolonged-Release Injectable Suspension (100 mg) in Subjects with Schizophrenia
Tolmar International Ltd0 个研究点目标入组 296 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 296
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Able to understand the investigational nature of this study and provide written informed consent prior to the participation in the trial
- •2.Subjects between 18 and 65 years of age (both inclusive)
- •3. Subjects having body mass index (BMI) between 18.50 to 30.00 kg/m2 (both inclusive)
- •4. Subjects diagnosed with schizophrenia as per DSM-IV-TR (or later) criteria.
- •5. Acceptable hematology status:
- •a. Hemoglobin >= 9 g/dL
- •b. Absolute neutrophil count (ANC) >= 1500 cells/μL
- •c. Platelet count >= 100,000 cells/μL
- •6. Acceptable liver function:
- •a. Alanine aminotransferase (ALT) <= 2X upper limit of normal (ULN)
- •b. Aspartate aminotransferase (AST) <= 2X ULN
- •c. Bilirubin < 1.2 mg/dL
- •d. Alkaline phosphatase <= 2X ULN
- •7. Subjects with creatinine clearance >= 80 mL/minute
- •8. Female subjects with negative serum pregnancy test at screening.
- •9. Subjects who agree to use adequate contraception (e.g., hormonal, chemical, double-barrier, or abstinence) while in the study and for 3 months after study participation is discontinued
- •10. No history of addiction to any recreational drug or drug dependence or alcohol addiction within 12 months prior to randomization
- •11. Must be able to attend regularly scheduled study center appointments and be able to abide by all study requirements
排除标准
- •1. Hypersensitivity to paliperidone palmitate or risperidone or to any of the excipients of the formulations
- •2. Subjects who are in an acutely agitated or severely psychotic state
- •3. Subjects who have current thoughts of suicide (suicidal ideation) or violent tendencies at the time of screening
- •4. Subjects who have a Rating of >4 (moderately ill) on the CGI-S scale at screening
- •5. History or presence of neuroleptic malignant syndrome (NMS), tardive dyskinesia, dementia-related psychosis, Parkinsonâ??s disease or epilepsy/seizures
- •6. History or presence of any uncontrolled debilitating systemic disease (e.g., cardiovascular disease, hypertension, diabetes mellitus etc.)
- •7. Current or anticipated use during study participation of any of the prohibited medications. (See Appendix 14.1)
- •8. Subjects with congenital long QT syndrome (QTc of > 470 msec for females and > 450 msec for males) or presence of severe cardiovascular disease defined as having required cardiovascular surgery or the occurrence of incapacitating myocardial infarction within past 12 months
- •9.Subjects with history of arrhythmia
- •10. Subjects with positive urine screen for drugs of abuse (Except for benzodiazepine which is a permissible medication supported by prescription)
- •11. Smokers who smoke >= 10 cigarettes or equivalent per day
- •12. Major surgical procedure (including periodontal) within 28 days of first IP dosing
- •13. Current surgical or other non-healing wounds
- •14. Subjects with positive serology for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
- •15. Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study or that could limit adherence to study requirements
- •16. Participation in any clinical study within 90 days of first IP dosing
- •17. Donation and/or loss of >= 350 mL (1 unit) of blood within 90 days of first IP dosing
- •18. Lactating women
研究者
相似试验
已完成
不适用
Generic drug trial to seek approval for Paliperidone injectable suspension for treatment of Schizophrenia or Schizoaffective Disorder.CTRI/2019/08/020588Ryan Turncliff443
已完成
不适用
Generic drug trial to seek approval for Paliperidone 1 month injection for treatment of Schizophrenia.CTRI/2019/06/019840Tolmar International Ltd314
尚未招募
2 期
Multiple-dose pharmacokinetics and ex vivo pharmacodynamics of the fixed-dosed artemisinin based combination therapies (ACTs) of the antimalarial drugs Artequick (artemisinin-piperaquine) and Coarsucam (artesunate-amodiaquine) in healthy male Vietnamese volunteersACTRN12609000846224Australian Department of Defence44
已完成
1 期
Comparative assessment of the absorption of a generic formulation of melatonin prolonged release tablet against the innovator melatonin prolonged release tablet conducted under fasting conditions and at steady state in healthy male and female volunteersBioequivalence study conducted in healthy volunteers comparing two formulations of melatonin with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, melatonin is a naturally occurring hormone produced by the pineal gland and is indicated as monotherapy for the short term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.Bioequivalence study conducted in healthy volunteers comparing two formulations of melatonin with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, melatonin is a naturally occurring hormone produced by the pineal gland and is indicated as monotherapy for the short term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615000143527Zenith Technology Corp Ltd28
已完成
1 期
Comparative assessment of the absorption of a generic formulation of quetiapine prolonged release tablet against the innovator quetiapine tablet conducted under fasting conditions and at steady state in healthy male and female volunteersBioequivalence study conducted in healthy volunteers comparing two formulations of quetiapine with no health condition or problem studied. Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, quetiapine belongs to a class of medicines called an atypical antipsychotic drug and is prescribed for the maintenance treatment of Bipolar and schizophrenia.Bioequivalence study conducted in healthy volunteers comparing two formulations of quetiapine with no health condition or problem studied.Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, quetiapine belongs to a class of medicines called an atypical antipsychotic drug and is prescribed for the maintenance treatment of Bipolar and schizophrenia.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12613001134718Zenith Technology Corporation Limited36